As shown in Figure 5A and 5B, significant decreases in the ALDH1+ population were observed in both MAPK (1%) and FAK (3.4%) inhibitor-treated cells, compared to the dimethyl sulphoxide (DMSO) control (7%), suggesting a role for these two pathways in maintaining the CRC ALDH+ population. The gene discussed is PTK2; the disease is colorectal carcinoma.